Physician profile
Omavi Bailey
NPI 1982010203
$246,350.52
in general payments reported to CMS, 2019-2025
17 companies · $130K in 2025
The $130K reported for 2025 was more than what 99% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $573 · 2021: $8,414 · 2022: $32K · 2023: $65K · 2024: $9,924 · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $132K · Consulting Fee: $35K · Travel and Lodging: $32K · Food and Beverage: $4,600 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $132,388.75 |
| Consulting Fee | $34,903.50 |
| Travel and Lodging | $32,161.72 |
| Food and Beverage | $4,599.70 |
| Education | $167.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $107,960.58 | 2025 | Zepbound |
| Harmony Biosciences LLC | $76,576.61 | 2020-2025 | Wakix |
| Idorsia Pharmaceuticals US INC | $38,554.88 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $9,619.55 | 2025 | |
| Novo Nordisk INC | $6,319.30 | 2025 | Wegovy |
| Eli Lilly and Company | $5,175.00 | 2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $447.38 | 2019-2025 | Xywav |
| Inspire Medical Systems, INC. | $427.69 | 2019-2023 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $401.17 | 2024-2025 | Lumryz |
| Zoll Respicardia, INC. | $362.65 | 2023 | Remede System |
| Watermark Medical, INC. | $143.48 | 2020 | |
| Itamar Medical INC | $136.85 | 2024 | Watchpatone |
| Abbott Laboratories | $103.86 | 2019 | |
| Boston Scientific Corporation | $52.62 | 2021-2024 | |
| Philips North America LLC | $36.97 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $19.65 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omavi Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.